ATE446514T1 - VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß - Google Patents

VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß

Info

Publication number
ATE446514T1
ATE446514T1 AT02727576T AT02727576T ATE446514T1 AT E446514 T1 ATE446514 T1 AT E446514T1 AT 02727576 T AT02727576 T AT 02727576T AT 02727576 T AT02727576 T AT 02727576T AT E446514 T1 ATE446514 T1 AT E446514T1
Authority
AT
Austria
Prior art keywords
respiratory distress
ßneonatal
ßhypoxia
2alphaß
treat
Prior art date
Application number
AT02727576T
Other languages
English (en)
Inventor
Veerle Compernolle
Peter Carmeliet
Original Assignee
Vlaams Interuniv Inst Biotech
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech, D Collen Res Foundation Vzw filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE446514T1 publication Critical patent/ATE446514T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02727576T 2001-04-24 2002-04-24 VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß ATE446514T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01201481 2001-04-24
EP01203073 2001-08-10
EP02075077 2002-01-11
PCT/EP2002/004479 WO2002086497A2 (en) 2001-04-24 2002-04-24 Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
ATE446514T1 true ATE446514T1 (de) 2009-11-15

Family

ID=27224281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727576T ATE446514T1 (de) 2001-04-24 2002-04-24 VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß

Country Status (8)

Country Link
US (2) US20050043227A1 (de)
EP (1) EP1407276B1 (de)
AT (1) ATE446514T1 (de)
AU (1) AU2002257794B8 (de)
CA (1) CA2444578C (de)
DE (1) DE60234100D1 (de)
DK (1) DK1407276T3 (de)
WO (1) WO2002086497A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737809B2 (en) * 2000-07-31 2004-05-18 Luxim Corporation Plasma lamp with dielectric waveguide
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005034929A2 (en) * 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
EP2347765B1 (de) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Verfahren zur Diagnose und Behandlung von Schwangerschaftskomplikationen
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
US8030446B2 (en) * 2006-02-10 2011-10-04 Trustees Of Dartmouth College Mutant proline-and-arginine rich peptides and methods for using the same
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
AU2007293475A1 (en) * 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US9345716B2 (en) * 2010-12-10 2016-05-24 Indian Institute Of Technology, Bombay Protein free surfactant composition for pulmonary diseases and a process for preparing the same
PL3417851T3 (pl) 2013-09-09 2020-12-14 Peloton Therapeutics, Inc. Etery arylowe i ich zastosowanie
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2016198121A1 (en) 2015-06-12 2016-12-15 Vib Vzw Means and methods for treating lung hypoplasia
US11510917B2 (en) * 2016-02-19 2022-11-29 Cornell University HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease
EP4410368A3 (de) * 2017-06-28 2024-11-27 Children's Medical Center Corporation Förderung des lungenwachstums
JP7384815B2 (ja) * 2018-03-22 2023-11-21 ザ チルドレンズ メディカル センター コーポレーション 肺の修復に関する方法および組成物
EP3659505A1 (de) * 2018-11-28 2020-06-03 Koninklijke Philips N.V. Relevanteste röntgenbildauswahl für hämodynamische simulation
CN112611877B (zh) * 2020-12-31 2022-09-16 四川大学华西医院 一款利用angptl4预测急性呼吸窘迫综合征患病及预后的试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5695963A (en) * 1997-01-17 1997-12-09 Board Of Regents, The University Of Texas System Endothelial PAS domain protein
EP0973926A1 (de) * 1997-03-14 2000-01-26 Selective Genetics, Inc. Adenovirale vektoren mit verändertem tropismus
WO2000009657A2 (en) * 1998-08-14 2000-02-24 President And Fellows Of Harvard College Methods of modulating of angiogenesis

Also Published As

Publication number Publication date
US7307060B2 (en) 2007-12-11
WO2002086497A3 (en) 2004-01-08
US20050043227A1 (en) 2005-02-24
CA2444578C (en) 2010-12-14
AU2002257794A1 (en) 2002-11-05
AU2002257794B8 (en) 2007-02-15
EP1407276A2 (de) 2004-04-14
DK1407276T3 (da) 2009-12-21
CA2444578A1 (en) 2002-10-31
US20060205645A1 (en) 2006-09-14
EP1407276B1 (de) 2009-10-21
DE60234100D1 (de) 2009-12-03
WO2002086497A2 (en) 2002-10-31
AU2002257794B2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
ATE446514T1 (de) VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
DE602004017174D1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
NO20065487L (no) Modulering av immunglobulinproduksjon og atopiske forstyrrelser
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EA200801515A1 (ru) Лиганды, которые связывают il-4 и/или il-13
DE60234873D1 (de) Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
DK2298338T3 (da) Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE60223058D1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ATE439834T1 (de) Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
EA200301195A1 (ru) Применение энантиомерно чистого эсциталопрама
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
ATE406884T1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
EP4181909A4 (de) Bispezifische antagonisten des retinolbindenden proteins 4 zur stabilisierung von transthyretintetrameren, ihre herstellung und verwendung bei der behandlung von gemeinsamen altersbedingten komorbiditäten
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE112005003750A5 (de) Verwendung von Moosen und/oder Flechten, Element und Verfahren zur Reduzierung des Feinstaubgehalts in der Luft
DE60140074D1 (de) Non-apoptotische formen des zelltods und verfahren zur modulation
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DE602004001509D1 (de) Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties